About
LiberoThera develops therapeutics targeting membrane proteins such as GPCRs by using proprietary cell-free membrane protein synthesis technologies and non-canonical amino acid incorporation.
Explore LiberoThera's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.